Indications
The Problem
Every year, millions of patients face costly and dangerous complications from local infections that systemic antibiotics often fail to treat effectively.
Such infections delay healing, extend hospital stays, and increase the need for repeat procedures — leading to severe health risks and more than $20 billion in annual healthcare costs in the U.S. alone.
Local infections — whether post-surgical, orthopedic, diabetic, or wound-related — remain difficult to eradicate because:
- Antibiotics are usually administered systemically, not directly to the infection site
- Blood circulation to the infected area is often impaired
- Prolonged systemic antibiotic use causes toxicity and antimicrobial resistance
Our Breakthrough Solution
GentaGel™ is a targeted, injectable, biodegradable polymer matrix that delivers high-dose antibiotics directly to the infection site.
It provides sustained release for up to 60 days, achieving ~6× higher local antibiotic levels than systemic treatments — without systemic side effects.
This innovation enables:
- Effective local infection control
- Reduced complications and re-interventions
- Faster recovery and wound closure
- Lower healthcare costs and improved outcomes
